Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor.
about
Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonistsBiased and g protein-independent signaling of chemokine receptorsAMD3100/CXCR4 InhibitorInhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitorsStructural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokineMolecular dynamics simulations on SDF-1alpha: binding with CXCR4 receptorFunctional reconstitution of the human chemokine receptor CXCR4 with G(i)/G (o)-proteins in Sf9 insect cellsMolecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.Identification of allosteric peptide agonists of CXCR4.Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemiaProtein recognition of macrocycles: binding of anti-HIV metallocyclams to lysozyme.Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomographyDistinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.HGF-induced PKCĪ¶ activation increases functional CXCR4 expression in human breast cancer cells.The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors.Impact of cytokines on replication in the thymus of primary human immunodeficiency virus type 1 isolates from infants.Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4.Structural Analysis of Chemokine Receptor-Ligand Interactions.Meninges control tangential migration of hem-derived Cajal-Retzius cells via CXCL12/CXCR4 signaling.Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: molecular modeling and experimental validation.Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465.Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.CXC chemokine CXCL12 and its receptor CXCR4 in tree shrews (Tupaia belangeri): structure, expression and function.Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies.Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling.AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates.A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemiaHomology modeling, docking, and molecular dynamics simulation of the receptor GALR2 and its interactions with galanin and a positive allosteric modulator.Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).CXC-chemokine receptor 4 antagonist AMD3100 promotes cardiac functional recovery after ischemia/reperfusion injury via endothelial nitric oxide synthase-dependent mechanism.HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cellsA small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice.Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamideSuccessful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large-volume leukapheresis.The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.
P2860
Q24802476-37CFB3AA-B58B-4A81-B308-9D59604FDED8Q26823970-EA8409BE-6881-4EB2-92AD-07A4C5F4A0FAQ28087445-1E6F2016-BA2C-483A-95AF-82A7D1ADD62AQ28274091-57D8F71F-EAB2-47D0-B2EB-CD051FD320BBQ28477736-C5485C4E-1E19-4B61-8803-BF664E78E919Q28910426-7AF08813-25DE-41F3-BAB9-25E630414EEEQ30332403-450980CE-728A-462A-AA6B-10C66B7123C2Q30438828-B59FCE74-F633-4FAF-9511-5BFE2B768E26Q30832371-C4989410-0ADB-45D2-B8D3-564C893032D3Q30868390-C2F546EC-57C5-4465-AC91-288590D5C60AQ31170483-94EA5687-7E92-41C8-88B8-4BC348F4CBA5Q33410331-55061DBA-ECAC-4D1C-844B-7F36CA05DA67Q33850234-54E1987D-57CF-40DC-902F-6E4662515AC5Q33867550-0498E260-1AFE-461B-A2DF-8752CE47F10FQ34055508-2C9B71C1-0C54-4273-AFFA-51C5F77E79ECQ34126591-B6AF38E7-43DC-4214-9DF6-75B8C4DBDCD1Q34313795-849CE641-7765-40E4-A667-3DD855A49B48Q34342452-0F858CC5-CA24-4C27-8948-37E711C05ADFQ34483653-1A627B8B-3DCD-404D-9DD2-C52E4552C78EQ34550666-BEC0EC77-4703-456C-AAD2-936ECF7C8576Q34565048-AE12C3A6-17D5-4F19-89F0-4120CE1C60E4Q34752104-E92AD0C3-5217-4085-A2B7-1CD5C5B7B18AQ35161921-17E8A99A-A796-41F2-A0AA-C795FC4B92C3Q35168976-0B11DAA5-B4F7-4E4D-922D-67D599692C79Q35173452-FB57D4B0-0F0B-4F5F-AA1B-6A49EE82BD5EQ35528569-0FD91E85-AFBA-4291-9903-C901EBC79F93Q35788749-21EA32DB-25AB-420C-A99F-09340A0857C8Q35849653-EDB86D54-6BFB-407F-99CD-42FE8EFDA918Q35953355-091DD70C-BCF6-4D47-98AF-4DD9B08FC48EQ35972120-3912B9E1-07B2-43BF-AC73-E36D1A339722Q36098903-82748FE9-3AA4-452E-BE58-C3E3E847F0D8Q36334083-8DB931CA-91A3-4A55-9FF3-D1145620EA99Q36576314-087AE1DA-781C-4AF8-9B7C-B1A96F092E83Q36919844-2BC95CD7-1401-4F0B-8FB8-D9B6238A5882Q37089440-5538A265-D573-447D-AD12-C69D87483840Q37099769-57AB7A04-1E37-423F-BDFA-40388748B226Q37136281-1FD88BC9-6048-4AC5-8AA8-F1C08A6A2EEBQ37180930-3C8F2002-24C1-4B43-9467-6FF627622BACQ37247686-848F6C9D-4EFA-4031-9192-E5CC5D8ECAE4Q37337280-7393563F-8D5A-4541-A48F-2880C35A7699
P2860
Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor.
description
2001 nĆ® lÅ«n-bĆ»n
@nan
2001 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« Õ
ÕøÖÕ¶ÕøÖÕ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2001 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ°ÕøÖÕ¶Õ¾Õ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2001幓ć®č«ę
@ja
2001幓č«ę
@yue
2001幓č«ę
@zh-hant
2001幓č«ę
@zh-hk
2001幓č«ę
@zh-mo
2001幓č«ę
@zh-tw
2001幓č®ŗę
@wuu
name
Molecular interactions of cycl ...... the CXCR4 chemokine receptor.
@ast
Molecular interactions of cycl ...... the CXCR4 chemokine receptor.
@en
type
label
Molecular interactions of cycl ...... the CXCR4 chemokine receptor.
@ast
Molecular interactions of cycl ...... the CXCR4 chemokine receptor.
@en
prefLabel
Molecular interactions of cycl ...... the CXCR4 chemokine receptor.
@ast
Molecular interactions of cycl ...... the CXCR4 chemokine receptor.
@en
P2093
P356
P1476
Molecular interactions of cycl ...... the CXCR4 chemokine receptor.
@en
P2093
Bridger GJ
Gerlach LO
Schwartz TW
P304
14153-14160
P356
10.1074/JBC.M010429200
P407
P577
2001-01-11T00:00:00Z